Dasabuvir Sodium Hydrate/Paritaprevir/Ombitasvir/Ritonavir

达塞布韦钠/帕利普韦/奥比他韦/利托那韦

Report date: 2022/06/15 16:53:48
First In Class

Base Information

Drug NameDasabuvir Sodium Hydrate/Paritaprevir/Ombitasvir/Ritonavir
Drug Alias Namedasabuvir, ombitasvir, paritaprevir and ritonavirRitonavir/Dasabuvir Sodium Hydrate/Paritaprevir/OmbitasvirViekira XrViekira PakABT-450/ritonavir/ABT- 267/dasabuvir
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionHuman immunodeficiency virus type 1 protease inhibitorsHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitorsHepatitis C virus serine protease, NS3/NS4A inhibitors +[4] 
TargetsHepatitis C virus NS5B RNA-dependent RNA polymeraseHuman immunodeficiency virus type 1 proteaseNonstructural protein 5A +[4] 
Therapy Area/IndicationsHepatitis C, ChronicHepatitis C
Global Approved IndicationsHepatitis C
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2014/12/19
Country/TerritoryUnited States
CombinationsYes Dasabuvir Sodium HydrateParitaprevirOmbitasvir
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbbvie Inc
Active IndicationsN/A
Inactive IndicationsHepatitis C, ChronicHepatitis C

Other Information

ATC CodeJ05AP52
Related LinksWikipediaKEGG